| 注册
首页|期刊导航|山东医药|骨肉瘤组织中COX-2、VEGF的表达及意义

骨肉瘤组织中COX-2、VEGF的表达及意义

马隽 陈晓明 钟艳平 黎丹戎 肖增明

山东医药2011,Vol.51Issue(10):7-9,3.
山东医药2011,Vol.51Issue(10):7-9,3.

骨肉瘤组织中COX-2、VEGF的表达及意义

Expression and significance of COX-2 and VEGF in osteosarcoma

马隽 1陈晓明 2钟艳平 3黎丹戎 3肖增明2

作者信息

  • 1. 广西医科大学研究生学院,南宁530021
  • 2. 广西医科大学第一附属医院
  • 3. 广西医科大学医学科学实验中心
  • 折叠

摘要

Abstract

Objective To investigate the expression of cyclooxygenase 2 (COX-2) and vascular endothelial growth factor (VEGF) in osteosarcoma and explore the significance.Methods 45 patients with osteosarcoma were treated with amputation or prosthesis replacement.Osteosarcoma and corresponding adjacent ( > 5.0 cm at the outer edge of the tumor tissue) tissue samples were obtained during operation.The expression of COX-2, VEGF and MVD marked by CD34 of osteosarcoma and their adjacent tissues were detected by immuno histochemistry.Results The positive rates of COX-2, VEGF and MVD in osteosarcoma tissues were 80.0%, 75.6% and (43.6 ± 11.4) stripe/HP, respectively, which were higher than those in adjacent tissues(P all <0.05).In patients with osteosarcoma, the expression of COX-2, VEGF and MVD were associated with Enneking stage( P all <0.05).There was a positive relationship between the expression of COX-2 and VEGF,the expression of COX-2 and VEGF were positively correlated with MVD ( r = 0.75, 0.58, respectively, P all < 0.05).The MVD values in both COX-2 and VEGF positive samples were higher than those in COX-2 negative and VEGF negative samples (P < 0.05).Conclusions COX-2 and VEGF are highly expressed in asteosarcoma and expression of them are associated with surgical stage of osteosarcoma, may involved in the occurrence and development of osteosarcoma, the mechanism maybe contributing to angiogenesis in osteosarcoma.

关键词

骨肿瘤/骨肉瘤/环氧化酶2/血管内皮生长因子/微血管密度

Key words

bone tumor/ osteosarcoma/ cyclooxygenase-2/ vascular endothelial growth factor/ microvessel density

分类

医药卫生

引用本文复制引用

马隽,陈晓明,钟艳平,黎丹戎,肖增明..骨肉瘤组织中COX-2、VEGF的表达及意义[J].山东医药,2011,51(10):7-9,3.

基金项目

广西壮族自治区自然科学基金资助项目(0832152). (0832152)

山东医药

1002-266X

访问量0
|
下载量0
段落导航相关论文